Biography for Amirah Al Idrus
Amirah Al Idrus, Copy Editor
Amirah Al Idrus is a copy editor for the FierceMarkets Life Sciences group and a contributing writer for FierceVaccines. Before joining the Fierce Life Sciences team, Amirah completed a master's degree in journalism at the University of Maryland, where she concentrated in multimedia journalism. While at Maryland, she worked for the university's Capital News Service as a web developer, and interned at the Washington Business Journal. She has covered issues ranging from Maryland politics and policy to prison finance. You can email her at firstname.lastname@example.org and follow her on Twitter at @AmirahFierce
Articles by Amirah Al Idrus
The World Health Organization has warned that the Zika R&D frenzy may not culminate in a vaccine in time for the current outbreak, but Sanofi Chief Scientific Officer Gary Nabel won't take that for an answer. Nabel says it can be done, but it means turning the traditional vaccine development model on its head.
Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.
Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.
South Korea's Green Cross announced a $32 million deal on Wednesday to supply its flu vaccines to the Pan American Health Organization, the WHO's regional office in the Americas.
Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.
The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.
Several players are working on vaccines for Middle East respiratory syndrome (MERS), including the NIH and tandem GeneOne and Inovio, both of which had successful animal trials for their candidates. Now, a new study out of South Korea--showing that the MERS virus mutated during the outbreak--could help vaccine developers pinpoint their target on the surface of the MERS virus.
Scientists have created the first 3-D "map" of a protein used by malaria parasites to invade human blood cells. This could lead to the development of a vaccine that could attack the most widespread species of the parasite.
With flu season in full swing, Mitsubishi Tanabe has its eyes on the horizon as it aims to get its quick-to-produce, tobacco-based flu vaccine on the market by 2018 or 2019. Nikkei Asian Review reported on Tuesday that the Osaka-based company has "all but finished" safety and efficacy trials of the vaccine in the U.S. and Canada and plans to run late-stage trials by the end of the year.
While it doesn't yet market any products, Inovio continues to be the Zika vaccine front-runner, reporting that its experimental jab induced a "robust and durable" immune response in mice.